Bengaluru based healthtech startup Inito has raised twenty nine million dollars in a Series B funding round led by Bertelsmann India Investments with continued support from existing investor Fireside Ventures. The company plans to use the capital to expand its offerings beyond fertility testing and build a comprehensive at home hormone and health diagnostics platform powered by AI. This latest round brings Inito’s total equity funding to approximately forty five million dollars.
Founded in 2021 by Aayush Rai and Varun AV Inito gained recognition for its at home fertility monitor that measures multiple hormone markers including FSH estrogen luteinizing hormone and progesterone metabolites on a single test strip. AI models then analyze the data to reveal hormone patterns track fertile windows and confirm ovulation. The product has processed over thirty million hormone data points since launch offering clinical grade insights without the need for lab visits.
With the new funding Inito plans to invest in AI designed antibodies that can increase the accuracy and sensitivity of at home diagnostic tests. Traditional antibodies used in diagnostics are grown in animals and screened manually which is slow and expensive. Inito’s computational approach predicts protein folding and allows synthetic antibodies to be designed in silico accelerating innovation and enabling tests for pregnancy progression menopause thyroid function and general endocrine health.
Inito currently operates teams in Bangalore Dubai and London and holds more than twenty patents related to its diagnostic technology. The co founders emphasize the vision that healthcare should begin at home and that individuals should be able to monitor important health indicators with confidence without waiting for lab reports or clinic appointments.
0 Comments